Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Frontiers in Pharmacology|July 3, 2019
mTORC1 Activation in Osteoclasts Prevents Bone Loss in a Mouse Model of OsteoporosisManami Hiraiwa, Kakeru Ozaki, Takanori Yamada, et al.Journal of Pharmacological Sciences|December 28, 2020
Daily oral supplementation of Hochu-Ekki-To prevents osteoclastic activation and bone loss in ovariectomized miceShinsuke Ochiai, Kazuya Tokumura, Gyujin Park, et al.Scientific Reports|August 3, 2016
ATF3 controls proliferation of osteoclast precursor and bone remodelingKazuya Fukasawa, Gyujin Park, Takashi Iezaki, et al.Molecular and Cellular Biology|July 7, 2016
Transcriptional Modulator Ifrd1 Regulates Osteoclast Differentiation through Enhancing the NF-κB/NFATc1 PathwayTakashi Iezaki, Kazuya Fukasawa, Gyujin Park, et al.Endocrinology|September 27, 2019
MAPK Erk5 in Leptin Receptor‒Expressing Neurons Controls Body Weight and Systemic Energy Homeostasis in Female MiceTetsuhiro Horie, Gyujin Park, Yuka Inaba, et al.Communications Biology|January 12, 2022
SMURF2 phosphorylation at Thr249 modifies glioma stemness and tumorigenicity by regulating TGF-β receptor stabilityManami Hiraiwa, Kazuya Fukasawa, Takashi Iezaki, et al.Stem Cell Reports|July 17, 2018
Translational Control of Sox9 RNA by mTORC1 Contributes to SkeletogenesisTakashi Iezaki, Tetsuhiro Horie, Kazuya Fukasawa, et al.Stem Cell Reports|July 1, 2022
The role of CDK8 in mesenchymal stem cells in controlling osteoclastogenesis and bone homeostasisTakanori Yamada, Kazuya Fukasawa, Tetsuhiro Horie, et al.Development (Cambridge, England)|July 11, 2018
The MAPK Erk5 is necessary for proper skeletogenesis involving a Smurf-Smad-Sox9 molecular axisTakashi Iezaki, Kazuya Fukasawa, Tetsuhiro Horie, et al.Journal of Cellular Physiology|September 26, 2022
Conditional inactivation of the L-type amino acid transporter LAT1 in chondrocytes models idiopathic scoliosis in miceSayuki Iwahashi, Jiajun Lyu, Kazuya Tokumura, et al.Pageof 3